TickerFacts.

A business in context

SRPT research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-08-05 · 0001193125-26-335056 · Items 2.02,9.01

  2. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-335003

  3. 4 · Ownership change

    Report date 2026-07-28 · 0001193125-26-324445

  4. 8-K · Current report

    Report date 2026-07-23 · 0001193125-26-316995 · Items 5.02,7.01,9.01

  5. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260263

  6. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260261

  7. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260259

  8. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260257

  9. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260255

  10. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260250

  11. 4 · Ownership change

    Report date 2026-06-04 · 0001193125-26-260246

  12. 8-K · Current report

    Report date 2026-06-04 · 0001193125-26-257501 · Items 5.02,5.07,9.01

  13. 8-K · Current report

    Report date 2026-05-06 · 0001193125-26-208966 · Items 2.02,9.01

  14. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-208893

  15. DEF 14A · Proxy statement

    Report date 2026-06-04 · 0001193125-26-177247

  16. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-084144

  17. 8-K · Current report

    Report date 2026-02-25 · 0001193125-26-072064 · Items 5.02

  18. 8-K · Current report

    Report date 2026-02-25 · 0001193125-26-071566 · Items 2.02,9.01

  19. 8-K · Current report

    Report date 2026-01-12 · 0001193125-26-010116 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2025-12-18 · 0001193125-25-326969 · Items 1.01,2.03,9.01

  21. 8-K · Current report

    Report date 2025-12-10 · 0001193125-25-315032 · Items 3.02,8.01,9.01

  22. 8-K · Current report

    Report date 2025-12-07 · 0001193125-25-310588 · Items 5.02,9.01

  23. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-269436

  24. 8-K · Current report

    Report date 2025-11-03 · 0001193125-25-262591 · Items 2.02,9.01

  25. 8-K · Current report

    Report date 2025-08-28 · 0001193125-25-192794 · Items 1.01,2.03,8.01,9.01

  26. 8-K · Current report

    Report date 2025-08-18 · 0001193125-25-184625 · Items 3.02

  27. 8-K · Current report

    Report date 2025-08-12 · 0001193125-25-179819 · Items 5.02

  28. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-103971

  29. 8-K · Current report

    Report date 2025-07-21 · 0001193125-25-161516 · Items 8.01

  30. 8-K · Current report

    Report date 2025-07-14 · 0000950170-25-096257 · Items 2.02,2.05,5.02,9.01

  31. 8-K · Current report

    Report date 2025-06-05 · 0000950170-25-083131 · Items 5.02,5.07,9.01

  32. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-064412

  33. DEF 14A · Proxy statement

    Report date 2025-06-05 · 0000950170-25-058003

  34. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-029973

  35. 8-K · Current report

    Report date 2025-02-26 · 0000950170-25-027717 · Items 2.02,9.01

  36. 8-K · Current report

    Report date 2025-02-13 · 0001193125-25-026683 · Items 1.01,2.03,9.01

  37. 8-K · Current report

    Report date 2025-01-13 · 0001193125-25-005160 · Items 2.02,9.01

  38. 8-K · Current report

    Report date 2024-11-24 · 0001193125-24-265627 · Items 1.01

  39. SC 13G/A · Ownership disclosure

    0001274173-24-000085

  40. SC 13G/A · Ownership disclosure

    0001562230-24-000064

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 8 transaction rows8AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

8 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-04
2026-06-05
Boor Kathryn JeanA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
Mayo StephenA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
Wigzell Hans Lennart RudolfA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
BEHRENS M KATHLEENA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
Connelly Deirdre PA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
Nicaise ClaudeA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
Chambers Michael AndrewA · Grant / award
Acquired
Common Stock16875.0—
2026-06-04
2026-06-05
Barry RichardA · Grant / award
Acquired
Common Stock16875.0—

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000873303Sarepta Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
549300IKDPIED8J8IG21
GLEIF legal name
SAREPTA THERAPEUTICS, INC.
Entity / LEI registration status
ACTIVE / ISSUED
Reference data updated
2026-08-05T18:40:05Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Sarepta Therapeutics · alias · wikidata
  • AVI BioPharma · alias · wikidata
  • Sarepta Therapeutics, Inc. · former SEC name · 2012-03-28 to 2026-08-14
  • AVI BIOPHARMA INC · former SEC name · 1998-11-17 to 2012-07-12
  • ANTIVIRALS INC · former SEC name · 1997-04-17 to 1998-05-12
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$1.90B$2.02B
2023-12-31$1.24B$1.36B
2022-12-31$933.01M$1.06B
2021-12-31$701.89M$864.79M
2020-12-31$540.10M$696.83M
2019-12-31$380.83M$497.38M
2018-12-31$301.03M$400.29M
2017-12-31$154.58M$210.58M

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗